Listing 1 - 10 of 10 |
Sort by
|
Choose an application
Development aid. Development cooperation --- SNV [The Hague] --- Ménaka
Choose an application
Development aid. Development cooperation --- Netherlands --- Benin --- Economic assistance, Dutch --- -Economic development projects --- -Development projects, Economic --- Projects, Economic development --- Economic assistance --- Technical assistance --- Dutch economic assistance --- Evaluation --- SNV Benin --- -SNV (Organization). --- Economic development projects --- Evaluation. --- -Evaluation --- Development projects, Economic --- SNV Bénin --- SNV (Organization).
Choose an application
The history of development cooperation has attracted very little research to date. This volume offers an innovative interpretation by considering the history of SNV Netherlands Development Organisation, which has been in existence for over forty years now. Through SNV’s history, an analysis emerges of the role of the Netherlands in development cooperation and the attitudes of Dutch society towards it over the last fifty years as well as the changing ideas, practices and policies in development work more generally. The views and expectations of (former) SNV staff and those of local participants who were ultimately to benefit from the development activities were the focus of this historical research. This has resulted in a socio-cultural history ‘from below’ rather than a dry description of the organisation’s administrative changes and formal bureaucratic structures.
Nonprofit organizations --- International agencies --- Economic assistance, Dutch --- Technical assistance, Dutch --- Economic development --- History. --- SNV (Organization)
Choose an application
Social organizations --- Development aid. Development cooperation --- Netherlands --- Economic assistance, Dutch --- Economic development --- International agencies --- Nonprofit organizations --- Technical assistance, Dutch --- History. --- SNV (Organization)
Choose an application
The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.
Research & information: general --- Chemistry --- acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody–drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy --- n/a --- antibody-drug conjugate
Choose an application
This ebook includes original research articles and reviews to update readers on the state of the art systems approach to not only discover novel diagnostic and prognostic biomarkers for several cancer types, but also evaluate methodologies to map out important genomic signatures. In addition, therapeutic targets and drug repurposing have been emphasized for a variety of cancer types. In particular, new and established researchers who desire to learn about cancer systems biology and why it is possibly the leading front to a personalized medicine approach will enjoy reading this book.
Sestrin2 --- lung cancer --- knockdown --- cancer progression --- bioinformatics --- patient survival --- lung adenocarcinoma --- circulating miR-1246 --- glycosaminoglycan binding --- prognosis --- PI3K–Akt signaling pathways --- TargetScan --- UBE2C --- cancer systems biology --- experimental model systems --- next-generation sequencing --- single-cell sequencing --- patient-derived xenografts --- patient-derived organoids --- triple-negative breast cancer --- personalized medicine --- computational methods --- drug repurposing --- clinical trials --- cancer stem cells --- ETS --- Elk-1 --- stem cell --- microarray --- brain-tumor-initiating cell (BTIC) --- pancreatic cancer --- systems biology --- omics --- biomarker --- genomics --- transcriptomics --- proteomics --- metabolomics --- glycomics --- metagenomics --- Ets --- PEA3 --- Ets-1 --- glioma --- optical genome mapping --- solid tumors --- cancer genomics --- breast --- ovarian --- cancer --- TCGA --- non-small-cell lung cancer --- lung adenocarcinoma (LUAD) --- lung squamous cell carcinoma (LUSC) --- differential expression --- SNV --- CNV --- risk group --- signature --- survival --- renal cancers --- protein interactome --- diagnostic biomarker --- prognostic biomarker --- virtual screening --- docking --- acute myeloid leukemia --- Boolean model --- drug resistance --- network --- n/a --- PI3K-Akt signaling pathways
Choose an application
The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.
acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody–drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy --- n/a --- antibody-drug conjugate
Choose an application
The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.
Research & information: general --- Chemistry --- acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody-drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy --- acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody-drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy
Choose an application
This ebook includes original research articles and reviews to update readers on the state of the art systems approach to not only discover novel diagnostic and prognostic biomarkers for several cancer types, but also evaluate methodologies to map out important genomic signatures. In addition, therapeutic targets and drug repurposing have been emphasized for a variety of cancer types. In particular, new and established researchers who desire to learn about cancer systems biology and why it is possibly the leading front to a personalized medicine approach will enjoy reading this book.
Medicine --- Sestrin2 --- lung cancer --- knockdown --- cancer progression --- bioinformatics --- patient survival --- lung adenocarcinoma --- circulating miR-1246 --- glycosaminoglycan binding --- prognosis --- PI3K-Akt signaling pathways --- TargetScan --- UBE2C --- cancer systems biology --- experimental model systems --- next-generation sequencing --- single-cell sequencing --- patient-derived xenografts --- patient-derived organoids --- triple-negative breast cancer --- personalized medicine --- computational methods --- drug repurposing --- clinical trials --- cancer stem cells --- ETS --- Elk-1 --- stem cell --- microarray --- brain-tumor-initiating cell (BTIC) --- pancreatic cancer --- systems biology --- omics --- biomarker --- genomics --- transcriptomics --- proteomics --- metabolomics --- glycomics --- metagenomics --- Ets --- PEA3 --- Ets-1 --- glioma --- optical genome mapping --- solid tumors --- cancer genomics --- breast --- ovarian --- cancer --- TCGA --- non-small-cell lung cancer --- lung adenocarcinoma (LUAD) --- lung squamous cell carcinoma (LUSC) --- differential expression --- SNV --- CNV --- risk group --- signature --- survival --- renal cancers --- protein interactome --- diagnostic biomarker --- prognostic biomarker --- virtual screening --- docking --- acute myeloid leukemia --- Boolean model --- drug resistance --- network --- Sestrin2 --- lung cancer --- knockdown --- cancer progression --- bioinformatics --- patient survival --- lung adenocarcinoma --- circulating miR-1246 --- glycosaminoglycan binding --- prognosis --- PI3K-Akt signaling pathways --- TargetScan --- UBE2C --- cancer systems biology --- experimental model systems --- next-generation sequencing --- single-cell sequencing --- patient-derived xenografts --- patient-derived organoids --- triple-negative breast cancer --- personalized medicine --- computational methods --- drug repurposing --- clinical trials --- cancer stem cells --- ETS --- Elk-1 --- stem cell --- microarray --- brain-tumor-initiating cell (BTIC) --- pancreatic cancer --- systems biology --- omics --- biomarker --- genomics --- transcriptomics --- proteomics --- metabolomics --- glycomics --- metagenomics --- Ets --- PEA3 --- Ets-1 --- glioma --- optical genome mapping --- solid tumors --- cancer genomics --- breast --- ovarian --- cancer --- TCGA --- non-small-cell lung cancer --- lung adenocarcinoma (LUAD) --- lung squamous cell carcinoma (LUSC) --- differential expression --- SNV --- CNV --- risk group --- signature --- survival --- renal cancers --- protein interactome --- diagnostic biomarker --- prognostic biomarker --- virtual screening --- docking --- acute myeloid leukemia --- Boolean model --- drug resistance --- network
Choose an application
This book focuses on the fundamental and applied research of the non-destructive estimation and diagnosis of crop leaf and plant nitrogen status and in-season nitrogen management strategies based on leaf sensors, proximal canopy sensors, unmanned aerial vehicle remote sensing, manned aerial remote sensing and satellite remote sensing technologies. Statistical and machine learning methods are used to predict plant-nitrogen-related parameters with sensor data or sensor data together with soil, landscape, weather and/or management information. Different sensing technologies or different modelling approaches are compared and evaluated. Strategies are developed to use crop sensing data for in-season nitrogen recommendations to improve nitrogen use efficiency and protect the environment.
Technology: general issues --- History of engineering & technology --- Environmental science, engineering & technology --- UAS --- multiple sensors --- vegetation index --- leaf nitrogen accumulation --- plant nitrogen accumulation --- pasture quality --- airborne hyperspectral imaging --- random forest regression --- sun-induced chlorophyll fluorescence (SIF) --- SIF yield indices --- upward --- downward --- leaf nitrogen concentration (LNC) --- wheat (Triticum aestivum L.) --- laser-induced fluorescence --- leaf nitrogen concentration --- back-propagation neural network --- principal component analysis --- fluorescence characteristics --- canopy nitrogen density --- radiative transfer model --- hyperspectral --- winter wheat --- flooded rice --- pig slurry --- aerial remote sensing --- vegetation indices --- N recommendation approach --- Mediterranean conditions --- nitrogen --- vertical distribution --- plant geometry --- remote sensing --- maize --- UAV --- multispectral imagery --- LNC --- non-parametric regression --- red-edge --- NDRE --- dynamic change model --- sigmoid curve --- grain yield prediction --- leaf chlorophyll content --- red-edge reflectance --- spectral index --- precision N fertilization --- chlorophyll meter --- NDVI --- NNI --- canopy reflectance sensing --- N mineralization --- farmyard manures --- Triticum aestivum --- discrete wavelet transform --- partial least squares --- hyper-spectra --- rice --- nitrogen management --- reflectance index --- multiple variable linear regression --- Lasso model --- Multiplex®3 sensor --- nitrogen balance index --- nitrogen nutrition index --- nitrogen status diagnosis --- precision nitrogen management --- terrestrial laser scanning --- spectrometer --- plant height --- biomass --- nitrogen concentration --- precision agriculture --- unmanned aerial vehicle (UAV) --- digital camera --- leaf chlorophyll concentration --- portable chlorophyll meter --- crop --- PROSPECT-D --- sensitivity analysis --- UAV multispectral imagery --- spectral vegetation indices --- machine learning --- plant nutrition --- canopy spectrum --- non-destructive nitrogen status diagnosis --- drone --- multispectral camera --- SPAD --- smartphone photography --- fixed-wing UAV remote sensing --- random forest --- canopy reflectance --- crop N status --- Capsicum annuum --- proximal optical sensors --- Dualex sensor --- leaf position --- proximal sensing --- cross-validation --- feature selection --- hyperparameter tuning --- image processing --- image segmentation --- nitrogen fertilizer recommendation --- supervised regression --- RapidSCAN sensor --- nitrogen recommendation algorithm --- in-season nitrogen management --- nitrogen use efficiency --- yield potential --- yield responsiveness --- standard normal variate (SNV) --- continuous wavelet transform (CWT) --- wavelet features optimization --- competitive adaptive reweighted sampling (CARS) --- partial least square (PLS) --- grapevine --- hyperparameter optimization --- multispectral imaging --- precision viticulture --- RGB --- multispectral --- coverage adjusted spectral index --- vegetation coverage --- random frog algorithm --- active canopy sensing --- integrated sensing system --- discrete NIR spectral band data --- soil total nitrogen concentration --- moisture absorption correction index --- particle size correction index --- coupled elimination
Listing 1 - 10 of 10 |
Sort by
|